Urogen Pharma (NASDAQ:URGN – Get Free Report)’s stock price reached a new 52-week high on Tuesday . The company traded as high as $35.35 and last traded at $34.99, with a volume of 624535 shares traded. The stock had previously closed at $33.57.
Analyst Upgrades and Downgrades
Several analysts have issued reports on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Urogen Pharma in a research note on Monday, April 20th. Oppenheimer restated an “outperform” rating on shares of Urogen Pharma in a report on Tuesday, June 2nd. D. Boral Capital restated a “buy” rating and issued a $33.00 price objective on shares of Urogen Pharma in a report on Tuesday, March 31st. HC Wainwright reaffirmed a “buy” rating and issued a $45.00 price objective on shares of Urogen Pharma in a research note on Wednesday, June 3rd. Finally, LADENBURG THALM/SH SH initiated coverage on shares of Urogen Pharma in a report on Monday, May 11th. They set a “buy” rating and a $43.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Urogen Pharma currently has a consensus rating of “Moderate Buy” and an average price target of $39.50.
View Our Latest Research Report on URGN
Urogen Pharma Stock Performance
Urogen Pharma (NASDAQ:URGN – Get Free Report) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.48) by $0.01. The company had revenue of $50.96 million for the quarter, compared to the consensus estimate of $44.83 million. As a group, research analysts expect that Urogen Pharma will post -0.98 EPS for the current year.
Insider Buying and Selling at Urogen Pharma
In other news, insider Mark Schoenberg sold 5,222 shares of the stock in a transaction that occurred on Monday, June 8th. The stock was sold at an average price of $27.30, for a total transaction of $142,560.60. Following the completion of the sale, the insider owned 139,763 shares of the company’s stock, valued at approximately $3,815,529.90. This represents a 3.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 4.80% of the company’s stock.
Institutional Investors Weigh In On Urogen Pharma
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in URGN. Mirae Asset Global Investments Co. Ltd. boosted its position in Urogen Pharma by 27.2% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,275 shares of the company’s stock valued at $53,000 after buying an additional 486 shares during the period. Russell Investments Group Ltd. increased its position in shares of Urogen Pharma by 1,594.4% in the third quarter. Russell Investments Group Ltd. now owns 3,321 shares of the company’s stock valued at $66,000 after acquiring an additional 3,125 shares during the period. Osaic Holdings Inc. raised its stake in shares of Urogen Pharma by 491.2% during the second quarter. Osaic Holdings Inc. now owns 3,695 shares of the company’s stock valued at $50,000 after acquiring an additional 3,070 shares during the last quarter. Tower Research Capital LLC TRC raised its stake in shares of Urogen Pharma by 422.0% during the second quarter. Tower Research Capital LLC TRC now owns 6,891 shares of the company’s stock valued at $94,000 after acquiring an additional 5,571 shares during the last quarter. Finally, ProShare Advisors LLC purchased a new stake in shares of Urogen Pharma during the fourth quarter worth about $206,000. 91.29% of the stock is currently owned by institutional investors.
About Urogen Pharma
UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.
The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.
Featured Stories
- Five stocks we like better than Urogen Pharma
- Buy CrowdStrike Before the Stock Split? Here’s the Case
- Investors Are Buying Into Sweetgreen Again—Should They?
- Burlington Is Winning Over Shoppers But Investors Need Patience
- USA Today’s Digital Revival Is Gaining Steam, But With Plenty of Risk
Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
